• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GlycoMimetics Inc.

    11/6/24 5:41:38 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLYC alert in real time by email
    SC 13G 1 tm2427451d3_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    GlycoMimetics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    38000Q102

    (CUSIP Number)

     

     

    October 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   38000Q102
     
    1

    Names of Reporting Persons

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF 

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    6,383,000

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    6,383,000

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,383,000

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%

     

    12

    Type of Reporting Person (See Instructions)

     

    IA, PN

     

           

     

     

     

    CUSIP No.   38000Q102
     
    1

    Names of Reporting Persons

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    6,383,000

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    6,383,000

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,383,000

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%

     

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

     

           

     

     

     

    CUSIP No.   38000Q102
     
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    6,383,000

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    6,383,000

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,383,000

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%

     

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

     

           

     

     

     

    CUSIP No.   38000Q102
     
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH 

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    6,383,000

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    6,383,000

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,383,000

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%

     

    12

    Type of Reporting Person (See Instructions)

     

    PN

     

           

     

     

     

    Item 1(a). Name of Issuer:

     

    GlycoMimetics, Inc. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    9708 Medical Center Drive, Rockville, MD 20850

     

    Item 2(a). Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c). Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships.

    Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e). CUSIP Number:

     

    38000Q102

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based upon 64,483,958 shares of Common Stock outstanding as of August 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024.

     

    The Fund directly holds 6,383,000 shares of Common Stock.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (“Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 6, 2024

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  

     

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

     

    Get the next $GLYC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLYC

    DatePrice TargetRatingAnalyst
    3/21/2025Overweight
    Cantor Fitzgerald
    7/26/2024Buy → Hold
    TD Cowen
    12/22/2023$12.00Overweight
    CapitalOne
    11/12/2021$3.00 → $4.00Hold → Buy
    Jefferies
    More analyst ratings

    $GLYC
    SEC Filings

    See more
    • Amendment: SEC Form S-4/A filed by GlycoMimetics Inc.

      S-4/A - GLYCOMIMETICS INC (0001253689) (Filer)

      4/28/25 8:17:20 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by GlycoMimetics Inc.

      425 - GLYCOMIMETICS INC (0001253689) (Subject)

      4/28/25 8:01:19 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GLYCOMIMETICS INC (0001253689) (Filer)

      4/28/25 8:00:46 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Financials

    Live finance-specific insights

    See more
    • GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

      Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim

      10/29/24 7:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

      Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3

      6/4/24 7:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

      Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company

      5/6/24 6:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on GlycoMimetics

      Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight

      3/21/25 8:14:54 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics downgraded by TD Cowen

      TD Cowen downgraded GlycoMimetics from Buy to Hold

      7/26/24 7:49:13 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on GlycoMimetics with a new price target

      CapitalOne initiated coverage of GlycoMimetics with a rating of Overweight and set a new price target of $12.00

      12/22/23 7:25:28 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GLYC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chief Medical Officer Rock Edwin bought $78,824 worth of shares (305,000 units at $0.26), increasing direct ownership by 81% to 680,403 units (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      6/24/24 4:29:48 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), increasing direct ownership by 33% to 70,643 units (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      6/20/24 4:15:39 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Rock Edwin bought $90,256 worth of shares (65,403 units at $1.38), increasing direct ownership by 21% to 375,403 units

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      9/25/23 4:21:40 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crescent Biopharma Appoints David Lubner to Board of Directors

      Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

      4/28/25 7:30:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

      Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly, as Chief Communications Officer Team Brings Deep Experience in Oncology Drug Development, Clinical Operations and Building Biotechnology Companies Lead Program CR-001, an Intentionally Designed Tetravalent PD-1 x VEGF Bispecific Antibody, on Track for IND Submission in Fourth Quarter of 2025; Company Advancing Pipeline of Novel ADCs WALTHAM, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel p

      4/3/25 7:30:31 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

      WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 9:10 am ET. A live webcast of the presentation will be available at https://wsw.com/webcast/cowen177/cresc/2175696. An archived recording will be available for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ:GLYC). Following

      2/26/25 8:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Invus Public Equities, L.P. sold $61,206 worth of shares (322,361 units at $0.19) (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      8/9/24 4:30:11 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Invus Public Equities, L.P. sold $41,184 worth of shares (220,255 units at $0.19) (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      8/7/24 4:30:11 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Invus Public Equities, L.P. sold $71,097 worth of shares (349,764 units at $0.20) (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      8/5/24 4:53:26 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Leadership Updates

    Live Leadership Updates

    See more
    • Crescent Biopharma Appoints David Lubner to Board of Directors

      Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

      4/28/25 7:30:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

      GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w

      9/6/22 7:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

      GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p

      3/2/22 9:15:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GlycoMimetics Inc.

      SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

      11/27/24 2:22:44 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GlycoMimetics Inc.

      SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)

      11/12/24 4:30:27 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GlycoMimetics Inc.

      SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

      11/6/24 5:41:38 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

      Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

      6/20/24 6:20:00 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care